Evidence map›Paper›PMID 35135481›Full record

Trial reportBMC nephrology2022

Potassium responses to sodium zirconium cyclosilicate in hyperkalemic hemodialysis patients: post-hoc analysis of DIALIZE.

Steven Fishbane, Martin Ford, Masafumi Fukagawa, Kieran McCafferty, Anjay Rastogi, Bruce Spinowitz, Konstantin Staroselskiy, Konstantin Vishnevskiy, Vera Lisovskaja, Ayman Al-Shurbaji and 2 more

Registry-linked trialOpen access · goldAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC nephrology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03303521 (A Phase 3b, Multicenter, Prospective, Randomized, Double Blind, Placebocontrolled Study to Reduce Incidence of Pre-dialysis Hyperkalemia With Sodium Zirconium Cyclosilicate), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03303521 phase3completednot on this map

A Phase 3b, Multicenter, Prospective, Randomized, Double Blind, Placebocontrolled Study to Reduce Incidence of Pre-dialysis Hyperkalemia With Sodium Zirconium Cyclosilicate (DIALIZE)

TypeinterventionalSponsorAstraZenecaRan2017 to 2018Enrolled196ConditionsHyperkalemiaArmsPlacebo, Sodium Zirconium Cyclosilicate (ZS)
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 10 institutions in 5 countries.

Steven FishbaneDepartment of Medicine, Zucker School of Medicine at Hofstra/Northwell, 100 Community Dr, Great Neck, NY, 11021, USA. Sfishbane@northwell.edu.
Martin FordDepartment of Renal Medicine, King's College Hospital NHS Trust, London, UK.
Masafumi FukagawaDivision of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan.ORCID 0000-0002-7832-2339
Kieran McCaffertyDepartment of Nephrology, Bart's Health NHS Trust, London, UK.ORCID 0000-0002-0762-2270
Anjay RastogiUCLA CORE Kidney Program, University of California Los Angeles, Los Angeles, CA, USA.
Bruce SpinowitzDepartment of Medicine, New York-Presbyterian Queens, Queens, NY, USA.
Konstantin StaroselskiyDepartment #2, B. Braun Avitum Russland Clinics, St Petersburg, Russia.
Konstantin VishnevskiyPropedeutics of Internal Diseases Chair, First Pavlov State Medical University of St Petersburg, St Petersburg, Russia.
Vera LisovskajaBiometrics and Information, AstraZeneca BioPharmaceuticals R&D Gothenburg, Mölndal, Sweden.
Ayman Al-ShurbajiGlobal Medicines Development, AstraZeneca BioPharmaceuticals R&D Gothenburg, Mölndal, Sweden.
Nicolas GuzmanGlobal Medicines Development, AstraZeneca BioPharmaceuticals R&D, Gaithersburg, MD, USA.
Sunil BhandariDepartment of Renal and Transplant Medicine, Hull University Teaching Hospitals NHS Trust, Hull, UK.ORCID 0000-0002-0996-9622
AstraZeneca (Sweden) · SEAstraZeneca (United States) · USBarts Health NHS Trust · GBFirst Pavlov State Medical University of St. Petersburg · RUHofstra University · USKing's College London · GBNew York Hospital Queens · USTokai University · JPUniversity of California, Los Angeles · USUniversity of Hull · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSodium zirconium cyclosilicate (SZC) is an effective and well-tolerated treatment for hyperkalemia in maintenance hemodialysis patients. In post-hoc analyses of the phase 3b DIALIZE study, we examined the spectrum of potassium responses to SZC.

methodsPost-hoc analyses with SZC and placebo included: the number of long interdialytic interval (LIDI) visits during the 4-week evaluation period where patients attained pre-dialysis serum potassium (sK

resultsA greater proportion of patients achieved the ranges of pre-dialysis sK

conclusionsThese analyses expand our knowledge of the spectrum of potassium responses with SZC in hyperkalemic hemodialysis patients.

trial registrationNCT03303521 .

Indexed as

Dialysis SolutionsDouble-Blind MethodFemaleHumansHyperkalemiaIon Exchange ResinsKidney Failure, ChronicMaleMiddle AgedPotassiumRenal DialysisSilicatesDialysis SolutionsIon Exchange ResinsPotassiumSilicatessodium zirconium cyclosilicateChronic kidney diseaseHemodialysisHyperkalemiaPotassiumSodium zirconium cyclosilicate

Identifiers

PMID35135481
PMCPMC8826669
OpenAlexW4210900746

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.